CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.63
0.03 (5.59%)
▲
5d:
+12.48%
30d:
-8.08%
90d:
-33.81%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTOR trades at premium valuation expecting 19.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CTOR trades at premium valuation expecting 19.2% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.63, which is considered fair relative to its 30-day fair value range of $0.57 to $0.70. From a valuation perspective, the stock is trading at a premium (Forward PE: 6.2) compared to its historical average (3.7). At these levels, the market is pricing in 19.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.51, while resistance sits at $0.73. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: CTOR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+539.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTOR is in a downtrend. Immediate support is located at $0.51, while resistance sits at $0.73. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: CTOR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+539.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.57 -
$0.70
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.8%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BULLISH: Trading 539.6% below Wall St target ($4.00)
- NEUTRAL: Trading at premium valuation - market expects 19.2% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$0.57 -
$0.70
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.51
Resistance Level
$0.73
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.25
Wall Street Target
$4.00
(+539.6%)
Valuation Premium vs History
+19.2% premium
PE vs Historical
6.3 vs 3.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+19.2%
(market-implied from PE analysis)
1-Year Target
$0.75
(+19%)
2-Year Target
$0.89
(+42%)
3-Year Target
$1.06
(+69%)
3-Yr Target (if PE normalizes)
(PE: 6→4)
PE COMPRESSION
$0.63
(+0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: August 04, 2026 5:27 AM ET
Data refreshes hourly during market hours. Next update: 6:27 AM
Data refreshes hourly during market hours. Next update: 6:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$112 | 52 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$663 | 48 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$113 | 45 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |